

Dacogen [decitabine]

Prior Authorization Request

CVS Caremark administers the prescription benefit plan for the patient identified. This patient's benefit plan requires prior authorization for certain medications in order for the drug to be covered. To make an appropriate determination, providing the most accurate diagnosis for the use of the prescribed medication is necessary. **Please respond below and fax this form to CVS Caremark toll-free at 1-855-330-1720**. If you have questions regarding the prior authorization, please contact CVS Caremark at **1-888-877-0518**. For inquiries or questions related to the patient's eligibility, drug copay or medication delivery; please contact the Specialty Customer Care Team: CaremarkConnect® 1-800-237-2767.

The recipient of this fax may make a request to opt-out of receiving telemarketing fax transmissions from CVS Caremark. There are numerous ways you may opt-out: The recipient may call the toll-free number at 877-265-2711, at any time, 24 hours a day/7 days a week. The recipient may also send an opt-out request via email to do_not_call@cvscaremark.com. An opt out request is only valid if it (1) identifies the number to which the request relates, and (2) if the person/entity making the request does not, subsequent to the request, provide express invitation or permission to CVS Caremark to send facsimile advertisements to such person/entity at that particular number. CVS Caremark is required by law to honor an opt-out request within thirty days of receipt.

	Date:
Patient's ID:	Patient's Date of Birth:
Physician's Name:	
Specialty:	NPI#:
Physician Office Telephone:	Physician Office Fax:
Referring Provider Info: ☐ Same as R	
Name: Fax:	NPI#: Phone:
Rendering Provider Info: 🗆 Same as R Name:	eferring Provider Same as Requesting Provider NPI#:
Fax:	Phone:
	t to dosing limits in accordance with FDA-approved labeling.
Approvals may be subject accepted com	t to dosing limits in accordance with FDA-approved labeling, pendia, and/or evidence-based practice guidelines.
Approvals may be subject accepted comp Required Demographic Information:	pendia, and/or evidence-based practice guidelines.
Approvals may be subject accepted compacted compacted Demographic Information: Patient Weight:	pendia, and/or evidence-based practice guidelineskg
Approvals may be subject accepted comp Required Demographic Information:	pendia, and/or evidence-based practice guidelineskg
Approvals may be subject accepted compacted compacted Demographic Information: Patient Weight: Patient Height:	pendia, and/or evidence-based practice guidelineskgcm
Approvals may be subject accepted compacted compacted Demographic Information: Patient Weight:	pendia, and/or evidence-based practice guidelines. kgcm e requested drug:

<u>Cri</u> 1.	teria Questions: What drug is being prescribed? □ Dacogen □ decitabine □ Other
2.	What is the patient's diagnosis? Myelodysplastic syndrome (MDS) Chronic myeloid leukemia (CML) Acute myeloid leukemia (AML) Accelerated phase or blast phase myelofibrosis Blastic plasmacytoid dendritic cell neoplasm (BPDCN) Myelodysplastic syndrome/myeloproliferative neoplasm (MDS/MPN) overlap neoplasms (i.e. chronic myelomonocytic leukemia [CMML], BCR-ABL negative atypical chronic myeloid leukemia [aCML], unclassifiable MDS/MPN, MDS/MPN with ring sideroblasts and thrombocytosis) Other
3.	What is the ICD-10 code?
4.	Is the patient currently receiving treatment with the requested medication? ☐ Yes ☐ No. If No. skip to #6 (if applicable).
5.	Is there evidence of unacceptable toxicity or disease progression on the current regimen? ☐ Yes ☐ No No further questions
Cor	nplete the following questions if the diagnosis is blastic plasmacytoid dendritic cell neoplasm (BPDCN).
6.	Does the patient have relapsed or refractory disease? ☐ Yes ☐ No
7.	Will the requested medication be used in combination with venetoclax? ☐ Yes ☐ No
	test that this information is accurate and true, and that documentation supporting this ormation is available for review if requested by CVS Caremark or the benefit plan sponsor.
X_	escriber or Authorized Signature Date (mm/dd/yy)
116	solibei of Authorized Signature Date (IIIII/du/yy)

Send completed form to: Case Review Unit CVS Caremark Specialty Programs Fax: 1-855-330-1720

Note: This fax may contain medical information that is privileged and confidential and is solely for the use of individuals named above. If you are not the intended recipient you hereby are advised that any dissemination, distribution, or copying of this communication is prohibited. If you have received the fax in error, please immediately notify the sender by telephone and destroy the original fax message. Dacogen (decitabine) SGM – 5/2021.

CVS Caremark Specialty Pharmacy

• 2211 Sanders Road NBT-6

• Northbrook, IL 60062

Phone: 1-888-877-0518

• Fax: 1-855-330-1720

• www.caremark.com